Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast

Journal of Pathology

Volumn 182, Issue 4, 1997, Pages 414-420

  Engels, K ^a   Fox, S B ^a   Whitehouse, R M ^a   Gatter, K C ^a   Harris, A L ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

angiogenesis; ductal carcinoma in situ; immunohistochemistry; platelet derived endothelial cell growth factor; thymidine phosphorylase

Indexed keywords

PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE;

EID: 0030799485     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q     Document Type: Article

References (49)

1. Bicknell R, Harris AL. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer 1991; 27: 781-785.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
3. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988; 48: 2083-2088.
4. Smith MK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994; 54: 800-804.
5. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237-1245.
6. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880-882.
7. Brem SS, M. JH, Gullino PM. Angiogenesis as a marker of pre-neoplastic lesions of the human breast. Cancer 1978; 41: 239-248.
8. Maiorana A, Gullino PM. Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 1978; 38: 4409-4414.
9. Ziehe M, Gullino PM. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 1982; 69: 483-487.
10. Guinebretiere JM, Le MG, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease (Letter; comment). J Natl Cancer Inst 1994; 86: 635-636.
11. Fregene TA, Kellog C, Pienta KJ. Microvessel quantitation as a measure of angiogenic activity in benign breast tissue lesions: a marker for precancerous disease? Int J Oncol 1994; 4: 1199-1202.
12. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high grade in-situ ductal carcinoma of the breast. J Pathol (submitted).
13. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86: 614-619.
14. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J Natl Cancer Inst 1992; 84: 1875-1887.
15. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama SI. Angiogenic factor. Nature 1992; 356: 668.
16. Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992; 31: 12141-12146.
17. Usuki K, Saras J, Waltenberger J, et al. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun 1992; 184: 1311-1316.
18. Barton GJ, Ponting CP, Spraggon G, Finnis C, Sleep D. Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase. 1992; 1: 688-690.
19. Finnis C, Dodsworth N, Pollitt CE, Carr G, Sleep D. Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem 1993; 212: 201-210.
20. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338: 557-562.
21. Haraguchi M, Kazutaka M, Uemura K, et al. Angiogenic activity of enzymes. Nature 1994; 368: 198.
22. Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res 1991; 3: 207-217.
23. Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998-1002.
24. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet derived endothelial cell growth factor/thymidine phosphorylase is upregulated in breast cancer epithelium and endothelium. Br J Cancer 1996; 73: 275-280.
25. Page DL, Anderson TJ, Rogers LW. Carcinoma in situ (CIS). In: Page DLAT, ed. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987; 157-192.
26. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990; 70: 853-871.
27. Poller DN, Silverstein MJ, Galea M, et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994; 7: 257-262.
28. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.
29. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
30. Fox SB, Moghaddam A, Westwood M, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 1995; 176: 183-190.
31. O'Brien TS, Fox SB, Dickinson AJ, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet derived endothelial cell growth factor in primary bladder cancer. Cancer Res 1996; 56: 4799-4804.
32. Panzeter PL, Ringer DP. DNA precursors are channelled to nuclear matrix DNA replication sites. Biochem J 1993; 293: 775-779.
33. Piper AA, Tattersall MHN, Fox RM. The activities of thymidine metabolising enzymes during the cell cycle of a human lymphocyte cell line LAZ-007 synchronised by centrifugal elutriation. Biochim Biophys Acta 1980; 633: 400-409.
34. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32: 333-338.
35. Ho CK, Ou BR, Hsu ML, Su SN, Yung CH, Wang SY. Induction of thymidine kinase activity and clonal growth of certain leukemic cell lines by a granulocyte-derived factor. Blood 1990; 75: 2438-2444.
36. O'Sullwan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993; 342: 148-149.
37. Polverini PJ, Leibovich SJ. Induction of neovascularisation in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-642.
38. Fox SB, Gatter KC, Bicknell R, et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53: 4161-4163.
39. Sholley M, Ferguson G, HR. S. Montour J, Wilson J. Mechanisms of neovascularization; vascular sprouting can occur without proliferation of endothelial cells. Lab Invest 1984; 51: 624-634.
40. Thompson WD, Shiach KJ, Fraser RA, McIntosh LC, Simpson JG. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J Pathol 1987; 151: 323-332.
41. Vlodavsky I, Korner G, Ishai MR, Bashkin P, Bar SR, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990; 9: 203-226.
42. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990; 87: 6624-6628.
43. Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F. Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res 1990; 50: 4131-1138.
44. Iruela AM, Bornstein P, Sage H. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 5026-5030.
45. Moses MA, Langer R. Metalloproteinase inhibition as a mechanism for the inhibition of angiogenesis. Exs 1992; 61: 146-151.
46. Stetler SW, Krutzsch HC, Liotta LA. TIMP-2: identification and characterization of a new member of the metalloproteinase inhibitor family. Matrix 1992; I: 299-306.
47. Vogel T, Guo NH, Krutzsch HC, et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993; 53: 74-84.
48. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85: 1045-1049.
49. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995; 1: 961-964.